Cytel, Suvoda Announce Partnership at the Drug Information Association (DIA) 50th Annual Meeting - Applied Clinical Trials

ADVERTISEMENT

See our 2013 Buyers Guide Digital Edition.
Cytel, Suvoda Announce Partnership at the Drug Information Association (DIA) 50th Annual Meeting

Source: Company News Release

Cytel Inc., a leading provider of adaptive trial design software, strategic consulting and clinical research services, and Suvoda LLC, an innovative provider of Interactive Response Technology (IRT) jointly announced a complimentary partnership during the Drug Information Association’s (DIA) annual meeting in San Diego.

Customers will have access to an array of Cytel’s validated predictive analytics and trial implementation support technologies when choosing the Suvoda IRT product.

“We want our customers to get the best possible guidance in the critical areas of randomization and trial supply management. Integrated access to Cytel’s expertise will be invaluable to our clients when designing and conducting the increasingly complex study protocols we are seeing today”, said Jagath Wanninayake, founder & CEO of Suvoda.

Senior Vice President for Cytel Clinical Research Services, Irving Dark said of the partnership, “The partnership between Cytel and Suvoda underscores our commitment to delivering world‐class statistical software and predictive analytics to improve success rates in drug development. Coupling Suvoda’s cutting‐edge IRT solution with Cytel’s robust software suite will enable sponsors to leverage the combined power of our respective expertise in a seamless and efficient manner.”

The two companies will announce specific capabilities as their integration efforts progress. At DIA, learn more from Cytel and Suvoda representatives at Cytel booth #725.

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
86%
Borrow lightly from EMA's pathway program?
6%
Create entirely its own pathway program?
7%
View Results
Untitled Document
Source: Company News Release,
Click here